OTCPK:SRBC.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Sirona Biochem Corp. develops and sells cosmetic and pharmaceutical active ingredients in Canada and France.


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Sirona Biochem's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SRBC.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

4.1%

SRBC.F

0.4%

US Biotechs

2.3%

US Market


1 Year Return

-42.1%

SRBC.F

28.5%

US Biotechs

6.7%

US Market

Return vs Industry: SRBC.F underperformed the US Biotechs industry which returned 28.5% over the past year.

Return vs Market: SRBC.F underperformed the US Market which returned 6.7% over the past year.


Shareholder returns

SRBC.FIndustryMarket
7 Day4.1%0.4%2.3%
30 Day7.0%10.3%6.0%
90 Day2.8%23.2%18.9%
1 Year-42.1%-42.1%29.8%28.5%9.0%6.7%
3 Year71.1%71.1%31.8%27.5%36.6%27.7%
5 Year65.6%65.6%-5.1%-10.5%64.2%46.1%

Price Volatility Vs. Market

How volatile is Sirona Biochem's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Sirona Biochem undervalued compared to its fair value and its price relative to the market?

32.3x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SRBC.F's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SRBC.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SRBC.F is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: SRBC.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SRBC.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SRBC.F is overvalued based on its PB Ratio (32.3x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Sirona Biochem forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

30.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sirona Biochem has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Sirona Biochem performed over the past 5 years?

-6.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SRBC.F is currently unprofitable.

Growing Profit Margin: SRBC.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SRBC.F is unprofitable, and losses have increased over the past 5 years at a rate of -6.4% per year.

Accelerating Growth: Unable to compare SRBC.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SRBC.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: SRBC.F has a negative Return on Equity (-274.65%), as it is currently unprofitable.


Next Steps

Financial Health

How is Sirona Biochem's financial position?


Financial Position Analysis

Short Term Liabilities: SRBC.F's short term assets (CA$3.4M) exceed its short term liabilities (CA$342.9K).

Long Term Liabilities: SRBC.F's short term assets (CA$3.4M) exceed its long term liabilities (CA$1.2M).


Debt to Equity History and Analysis

Debt Level: SRBC.F's debt to equity ratio (60.6%) is considered high.

Reducing Debt: SRBC.F's debt to equity ratio has reduced from 86.6% to 60.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SRBC.F has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SRBC.F has less than a year of cash runway if free cash flow continues to grow at historical rates of 1.2% each year.


Next Steps

Dividend

What is Sirona Biochem current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SRBC.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SRBC.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SRBC.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SRBC.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SRBC.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.3yrs

Average management tenure


CEO

Howard Verrico (59yo)

6.08yrs

Tenure

CA$323,373

Compensation

Dr. Howard J. Verrico, M.D., Ph.D, is the Founder of Sirona Biochem Corp., has been Chief Executive Officer since June 18, 2014 and serves as its Secretary. Dr. Verrico served as the Chief Executive Office ...


CEO Compensation Analysis

Compensation vs Market: Howard's total compensation ($USD237.83K) is below average for companies of similar size in the US market ($USD614.21K).

Compensation vs Earnings: Howard's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Howard Verrico
Founder6.08yrsCA$323.37k3.69% CA$1.7m
Christopher Hopton
CFO & Director9.5yrsCA$212.60k0.42% CA$190.3k
Géraldine Deliencourt-Godefroy
Chief Scientific Officer & Director9.33yrsCA$252.39k4.6% CA$2.1m
Michelle Seltenrich
Vice President of Operationsno datano datano data
Brett Premack
Scientific Consultant8.33yrsno datano data

8.3yrs

Average Tenure

Experienced Management: SRBC.F's management team is seasoned and experienced (8.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Howard Verrico
Founder6.08yrsCA$323.37k3.69% CA$1.7m
Christopher Hopton
CFO & Director9.5yrsCA$212.60k0.42% CA$190.3k
Géraldine Deliencourt-Godefroy
Chief Scientific Officer & Director9.33yrsCA$252.39k4.6% CA$2.1m
Michael Walker
Member of the Scientific Advisory Board10.67yrsno datano data
Alex Marazzi
Independent Director13.75yrsCA$7.89k1.18% CA$528.4k
Denis Richard
Member of the Scientific Advisory Board10.67yrsno datano data
Bruce Verchere
Member of the Scientific Advisory Board10.67yrsno datano data
Caigan Du
Member of Scientific Advisory Board4.25yrsno datano data
Jason Tian
Independent Director1.08yrsno data1.33% CA$599.7k

10.1yrs

Average Tenure

57yo

Average Age

Experienced Board: SRBC.F's board of directors are seasoned and experienced ( 10.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12%.


Top Shareholders

Company Information

Sirona Biochem Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sirona Biochem Corp.
  • Ticker: SRBC.F
  • Exchange: OTCPK
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$61.104m
  • Listing Market Cap: CA$44.940m
  • Shares outstanding: 226.31m
  • Website: https://www.sironabiochem.com

Location

  • Sirona Biochem Corp.
  • 605 – 889 West Pender Street
  • Vancouver
  • British Columbia
  • V6C 3B2
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SBMTSXV (TSX Venture Exchange)YesCommon SharesCACADMay 2009
ZSBDB (Deutsche Boerse AG)YesCommon SharesDEEURMay 2009
SRBC.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMay 2009

Biography

Sirona Biochem Corp. develops and sells cosmetic and pharmaceutical active ingredients in Canada and France. The company develops programs in the areas of diabetes, anti-inflammatories, and anti-infectives for therapeutics; anti-aging and depigmenting agents in cosmeceuticals; and biological ingredients, such as inducers and adjuvants for the biological development and preservation. It develops a sodium glucose co-transporter inhibitor for the treatment of diabetes, as well as cosmetic skin lightening agents and compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/13 00:39
End of Day Share Price2020/07/09 00:00
Earnings2020/04/30
Annual Earnings2019/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.